Version 1
: Received: 3 June 2023 / Approved: 5 June 2023 / Online: 5 June 2023 (04:13:02 CEST)
How to cite:
Hurwitz, J.; Haggstrom, L.R.; Lim, E. Antibody Drug Conjugates: Ushering in a New Era of Cancer Therapy. Preprints2023, 2023060232. https://doi.org/10.20944/preprints202306.0232.v1
Hurwitz, J.; Haggstrom, L.R.; Lim, E. Antibody Drug Conjugates: Ushering in a New Era of Cancer Therapy. Preprints 2023, 2023060232. https://doi.org/10.20944/preprints202306.0232.v1
Hurwitz, J.; Haggstrom, L.R.; Lim, E. Antibody Drug Conjugates: Ushering in a New Era of Cancer Therapy. Preprints2023, 2023060232. https://doi.org/10.20944/preprints202306.0232.v1
APA Style
Hurwitz, J., Haggstrom, L.R., & Lim, E. (2023). Antibody Drug Conjugates: Ushering in a New Era of Cancer Therapy. Preprints. https://doi.org/10.20944/preprints202306.0232.v1
Chicago/Turabian Style
Hurwitz, J., Lucy Roxana Haggstrom and Elgene Lim. 2023 "Antibody Drug Conjugates: Ushering in a New Era of Cancer Therapy" Preprints. https://doi.org/10.20944/preprints202306.0232.v1
Abstract
Antibody-drug conjugates (ADCs) have provided new therapeutic options and significant promise for patients with cancers, particularly where existing treatments are limited. Substantial effort in ADC development is underway globally, with 13 ADCs currently approved and many more in development [1]. Therapeutic benefits of ADCs leverage the ability to selectively target cancer cells through antibody binding, resultant relative sparing of non-malignant tissues, and the targeted delivery of a cytotoxic payload. Consequently, this drug class has demonstrated activity in multiple malignancies refractory to standard therapeutic options [1-4]. Despite this, limitations exist, including narrow therapeutic windows, unique toxicity profiles, development of therapeutic resistance, and appropriate biomarker selection [5-7]. This review will describe the development of ADCs, their mechanisms of action, pivotal trials, and approved indications and identify common themes. Current challenges and opportunities will be discussed for this drug class in cancer therapeutics at a time when significant developments in antibody therapies, immunotherapy and targeted agents are occurring.
Keywords
Antibody-drug conjugate; cancer; clinical trials
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
